(NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune ...
Tarlatamab showed promising antitumor activity in heavily pretreated SCLC patients, including those with untreated brain metastases. Real-world data indicated higher rates of CRS and ICANS compared to ...
Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has shown clinical activity in pretreated patients with several tumor types, including colorectal cancer. Preclinical studies ...
Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be classified into three classes according to ...
Please provide your email address to receive an email when new articles are posted on . Older age and high clinical activity score lowered the odds for response to glucocorticoids in thyroid eye ...
Chemoradiation and Image-Guided Brachytherapy Alone or in Combination With Protease Inhibitor (Nelfinavir Mesylate) in Stage III Cervical Cancer: Results From a Phase III Trial Exarafenib's maximal ...
MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results